Home Share Market Novartis, MMV to advance new malaria therapy in phase 3 trial

Novartis, MMV to advance new malaria therapy in phase 3 trial


JHVEPhoto/iStock Editorial via Getty Images

Novartis (NYSE:NVS) and Medicines for Malaria Venture (MMV) have decided to advance ganaplacide/lumefantrine- solid dispersion formulation (SDF) into phase 3 development to treat patients with acute uncomplicated malaria due to Plasmodium falciparum.

The Swiss pharma giant said that ganaplacide is a novel agent with a new mechanism of action and the combination also contains a new formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration.

Novartis added that the combination has the potential not only to clear malaria infection, including artemisinin-resistant strains, but also to block the transmission of the malaria parasite.

“We need non-artemisinin-based medicines with novel mechanisms of action against resistant parasites, and simple, easy-to-follow dosing schedules to help increase treatment adherence,” said Dr Sujata Vaidyanathan, head Global Health Development Unit, Novartis.

The drug is being developed with scientific and financial support from MMV and their partners.

The phase 3 study is planned to start in 2023 and will evaluate ganaplacide/lumefantrine-SDF to the current ‘gold standard’ artemether-lumefantrine, the company added.

Novartis said that the trial will be conducted in collaboration with the WANECAM 2 consortium, and will include partner clinical sites in Burkina Faso, Mali, Gabon and Niger and in sub-Saharan Africa.

The company noted that a phase 2 trial in 524 adults and children with acute uncomplicated malaria due to Plasmodium falciparum infection had met its main goal.

The ganaplacide/lumefantrine-SDF combo had received fast track and orphan drug designations in the U.S. in August to treat acute, uncomplicated malaria.



Source link

RELATED ARTICLES

Up 14% in November, can Rolls-Royce shares hit £1 in December?

As a shareholder in Rolls-Royce (LSE: RR), 2022 so far has not been a banner year. Rolls-Royce shares have fallen 29% since...

Asia-Pacific markets largely higher despite disappointing China’s factory activity data

Japan -0.21%. Japan data - October preliminary industrial production -2.6% m/m (expected -1.5%). China -0.16%. China official Manufacturing PMI 48.0 (expected 49.0) &...

BOJ flags broadening price increases in once deflation-prone Japan By Reuters

© Reuters. FILE PHOTO: People wait for change of traffic sign in front of a shop at Ginza shopping district in Tokyo, Japan,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Official: Toxic fire suppressant spill in Hawaii ‘egregious’

A cleanup is underway after about 1,100 gallons of toxic fire suppressant was spilled at the Navy’s Red Hill fuel facility Tuesday, according...

Japan looks for counterstrike missile capabilities: reports

Japan’s efforts to bolster its defense against growing threats in the region are currently underway, which includes looking into acquiring counterstrike capabilities, according...

Crypto Exchange Kraken Settles With Treasury Department Over Sanctions Violations – Regulation Bitcoin News

Crypto exchange Kraken has settled with the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC) over its apparent violations of...

Recent Comments